Skip to main content
Fig. 7 | Arthritis Research & Therapy

Fig. 7

From: Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling

Fig. 7

Emab inhibits the generation of Blimp1+ cells. Sorted CD19+CD10CD27IgD tonsillar B cells were left untreated or stimulated with R848, anti-human F(ab′)2 IgM or a combination of R848 plus anti-IgM in the presence of Emab or isotype control Ab. a Representative flow cytometry data, showing intracellular Blimp1 expression within CD10CD27IgD B cells after 3 days of cell culture in the presence of Emab (black line) or an isotype-matched control Ab (gray line). PE-conjugated rat IgG2a was used as a staining control (dotted tinted line). b Representative flow cytometry data showing CD20 and intracellular Blimp1 expression within CD10CD27IgD cells after 3 days of cell culture. Gates depict frequencies of CD20loBlimp1+ cells. c Summary results from three independent experiments showing the percentage of CD20loBlimp1+ from total live cells in culture after cell stimulation in the presence or absence of Emab. **p < 0.01, as determined by unpaired Student’s t test. Emab epratuzumab

Back to article page